- •A small proportion (13%) of CF lung transplant recipients have been prescribed ETI.
- •Most recipients were prescribed ETI for sinus disease or GI symptoms.
- •Many (30–40%) CF lung transplant recipients stopped ETI due to side effects.
- •Hemoglobin and hemoglobin A1c may improve with ETI use after transplant.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele.N Engl J Med. 2019; 381: 1809-1819
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.Lancet N Am Ed. 2019; 394: 1940-1948
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.N Engl J Med. 2011; 365: 1663-1672
- The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.Ann Am Thorac Soc. 2020; 17: 147-154
- Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation.Clin Transl Gastroenterol. 2017; 8: e81
- Growth in prepubertal children with cystic fibrosis treated with ivacaftor.Pediatrics. 2017; 139
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.Pediatr Diabetes. 2013; 14: 417-421
- Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.J Cyst Fibros. 2021; 20: 460-463
- Elexacaftor/ivacaftor/tezacaftor in lung transplant recipients: a case series.J Heart Lung Transplant. 2021; 40: S375
- To treat or not to treat: CFTR modulators after lung transplantation.Pediatr Transplant. 2021; 25: e14007
- Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy.Am J Respir Crit Care Med. 2019; 199: 342-351
- The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.J Cyst Fibros. 2022; 21: 258-263
- CFTR modulator use is associated with higher hemoglobin levels in individuals with cystic fibrosis.Ann Am Thorac Soc. 2018; 16: 331-340
- Immune responses in cystic fibrosis: are they intrinsically defective?.Am J Respir Cell Mol Biol. 2012; 46: 715-722
- CFTR modulator therapy enhances peripheral blood monocyte contributions to immune responses in people with cystic fibrosis.Front Pharmacol. 2020; 11: 1219
- Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis.ERJ Open Res. 2020; 6
- Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis.Am J Respir Cell Mol Biol. 2016; 54: 594-597
- Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review.J Clin Med. 2021; 10: 23
- Impact of cftr therapy on chronic rhinosinusitis and health status: deep learning ct analysis and patient reported outcomes.Ann Am Thorac Soc. 2022; 19: 12-19
- Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against Pseudomonas aeruginosa.Am J Rhinol Allergy. 2019; 33: 129-136
- Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients.Respiration. 2013; 86: 25-31
- Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the Pulmonary council of the ISHLT.J Heart Lung Transplant. 2019; 38: 493-503
- Decreased antibiotic utilization after sinus surgery in cystic fibrosis patients with lung transplantation.Am J Rhinol Allergy. 2019; 33: 354-358
- Chronic rhinosinusitis in patients with cystic fibrosis-current management and new treatments.Laryngoscope Investig Otolaryngol. 2020; 5: 368-374
- Chronic kidney disease after nonrenal solid-organ transplantation.J Am Soc Nephrol. 2007; 18: 3031-3041
- Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.Eur Respir J. 2016; 47: 1697-1705
- Real-world long-term ivacaftor for cystic fibrosis in france: clinical effectiveness and healthcare resource utilization.Pulm Ther. 2021; 7: 455-468
- Long-term impact of ivacaftor on healthcare resource utilization among people with cystic fibrosis in the United States.Pulm Ther. 2021; 7: 281-293
- Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial.Am J Respir Crit Care Med. 2022; 205: 529-539
- Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: a two center case series.J Cyst Fibros. 2021; 20: 399-401